Results 11 to 20 of about 157,061 (320)

Prevalence of xylazine among people who inject drugs seeking medical care at a syringe services program clinic: Miami, Florida, 2023

Drug and Alcohol Dependence Reports, 2023
Background: We aimed to report the preliminary xylazine prevalence among people who inject drugs (PWID) treated at a student-run free clinic in Miami, FL, USA and to identify characteristics associated with screening positive for xylazine.
Maia H. Hauschild, Peyton V. Warp, Hansel E. Tookes, Ella Yakir, Bharat Malhotra, Subul Malik, Cyrus Owens, Edward Suarez, Jr, David P. Serota, Tyler S. Bartholomew   +9 more
doaj   +2 more sources

Managing xylazine-involved overdoses in a community harm reduction setting: lessons from Tijuana, Mexico

Harm Reduction Journal
Background Xylazine is a α2-adrenergic receptor agonist, used for sedation in veterinary contexts. Although it is increasingly found in overdose deaths across North America, the clinical management of xylazine-involved overdoses has not been extensively ...
Lilia Pacheco Bufanda, Alejando González Montoya, Brenda Torres Carrillo, Mariana Alejandra Gonzalez Tejeda, Luis A. Segovia, Alhelí Calderón-Villarreal, Joseph R. Friedman   +6 more
doaj   +2 more sources

Reported xylazine exposure highly associated with overdose outcomes in a rapid community assessment among people who inject drugs in Baltimore

Harm Reduction Journal
Background Addressing xylazine harms are now a critical harm reduction priority, but relatively little epidemiological information exists to determine prevalence, magnitude, and correlates of xylazine use or related outcomes. Methods We conducted a rapid
Danielle German, Becky Genberg, Olivia Sugarman, Brendon Saloner, Anne Sawyer, Jennifer L. Glick, Molly Gribbin, Colin Flynn   +7 more
doaj   +2 more sources

“Tranq-dope” overdose and mortality: lethality induced by fentanyl and xylazine

Frontiers in Pharmacology, 2023
Introduction: The recreational use of fentanyl in combination with xylazine (i.e., “tranq-dope”) represents a rapidly emerging public health threat characterized by significant toxicity and mortality.
Mark A. Smith, Samantha L. Biancorosso, Jacob D. Camp, Salome H. Hailu, Alexandra N. Johansen, Mackenzie H. Morris, Hannah N. Carlson   +6 more
doaj   +3 more sources

Public health impact and harm reduction implications of xylazine-involved overdoses: a narrative review

Harm Reduction Journal, 2023
Introduction Xylazine, an α2-adrenoceptor agonist sedative commonly used in veterinary medicine, is not approved for human use. Nevertheless, xylazine-involved overdose rates have surged in recent years, fueled by an increasingly toxic and synthetic ...
David T. Zhu
doaj   +2 more sources

Xylazine toxicity

The Southwest Journal of Medicine
Xylazine is a structural analog of clonidine and is an alpha-2 adrenergic receptor agonist. It is used in veterinary medicine for sedation, anesthesia, muscle relaxation, and analgesia, and it is often used with ketamine for anesthesia. Illicit drug use and overdose can result in severe mental and/or physical toxicity, including hallucinations ...
Anuhya Alapati, Kenneth Nugent
openaire   +2 more sources

Xylazine co-occurrence with illicit fentanyl is a growing threat in the Deep South: a retrospective study of decedent data

Harm Reduction Journal
Background Xylazine is a dangerous veterinary sedative found mainly in illicit fentanyl in the Northeast and Midwest. Its role in the Deep South overdose crisis is not well-characterized.
William Bradford, Mary Figgatt, Karen S. Scott, Stacy Marshall, Ellen F. Eaton, Daniel W. Dye   +5 more
doaj   +2 more sources

Illicitly Manufactured Fentanyl–Involved Overdose Deaths with Detected Xylazine — United States, January 2019–June 2022

MMWR. Morbidity and mortality weekly report, 2023
In 2022, provisional data indicated that more than two thirds (68%) of the reported 107,081 drug overdose deaths in the United States involved synthetic opioids other than methadone, principally illicitly manufactured fentanyls (IMFs) (1).
M. Kariisa, J. O'Donnell, Sagar Kumar, C. Mattson, B. Goldberger   +4 more
semanticscholar   +1 more source

Xylazine addiction turning humans to zombies: Fact or myth?

Health Sciences Review, 2023
Xylazine is a strong α-2 adrenergic agonist medication that was initially developed for use in veterinary medicine as an analgesic and sedative for animals.
Rabin Debnath, Pooja A Chawla
doaj   +1 more source

Opioid overdoses involving xylazine in emergency department patients: a multicenter study

Clinical toxicology, 2023
Introduction Illicit opioids, consisting largely of fentanyl, novel synthetic opioids, and adulterants, are the primary cause of drug overdose fatality in the United States.
J. Love, Michael D Levine, K. Aldy, J. Brent, A. Krotulski, B. Logan, Carmen C Vargas-Torres, Sara E. Walton, A. Amaducci, D. Calello, R. Hendrickson, Adrienne R. Hughes, Anita Kurt, B. Judge, A. Pizon, E. Schwarz, Joshua Shulman, Timothy Wiegan, P. Wax, A. Manini   +19 more
semanticscholar   +1 more source